Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Integrin beta-3 (β3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. The ITGB3 gene provides instructions for making the beta3 subunit of a receptor protein called integrin alphaIIb/beta3 (αIIbβ3), which is found on the surface of small cell fragments called platelets. Platelets circulate in blood and are an essential component of blood clots. The beta3 subunit attaches (binds) to the alphaIIb subunit, which is produced from the ITGA2B gene, to form integrin αIIbβ3. It is estimated that 80,000 to 100,000 copies of integrin αIIbβ3 are present on the surface of each platelet. During clot formation, integrin αIIbβ3 binds to a protein called fibrinogen. Attachment of integrin αIIbβ3 from adjacent platelets to the same fibrinogen protein helps platelets cluster together (platelet cohesion) to form a blood clot. Blood clots protect the body after injury by sealing off damaged blood vessels and preventing further blood loss. Integrin αIIbβ3 can also bind other proteins on platelets and in the blood as well as proteins within the intricate lattice that forms in the space between cells (extracellular matrix) to ensure proper clot formation and promote wound healing.
Associated Disease
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-T-1-L339-2 | Anti-ITGB3 scFv h(CD28) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-CD28 | Lentiviral | T cell | ||
| CAR-T-1-L339-G | Anti-ITGB3 scFv h(FcεRIγ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-FcεRIγ | Lentiviral | T cell | ||
| CAR-T-1-L339-Z | Anti-ITGB3 scFv h(CD3ζ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-L339-2G | Anti-ITGB3 scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-CD28-FcεRIγ | Lentiviral | T cell | ||
| CAR-T-2-L339-2Z | Anti-ITGB3 scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-L339-4G | Anti-ITGB3 scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-CD4-FcεRIγ | Lentiviral | T cell | ||
| CAR-T-2-L339-4Z | Anti-ITGB3 scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-CD4-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-L339-8Z | Anti-ITGB3 scFv h(CD8-CD3ζ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-CD8-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-L339-BZ | Anti-ITGB3 scFv h(41BB-CD3ζ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | ||
| CAR-T-2-L339-CZ | Anti-ITGB3 scFv h(b2c-CD3ζ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-b2c-CD3ζ | Lentiviral | T cell | ||
| CAR-T-3-L339-2BZ | Anti-ITGB3 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | ||
| CAR-T-3-L339-2XZ | Anti-ITGB3 scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 | Human | PM6/13 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
